Cargando…
Temporal genomic heterogeneity guiding individualized therapy in recurrent non-small cell lung cancer
INTRODUCTION: Despite the benefit of adjuvant systemic therapy for patients with resected non-small cell lung cancer (NSCLC), the risk of postoperative recurrence remains high. Our objective was to characterize temporal genetic heterogeneity between primary resected and recurrent tumors, and its imp...
Autores principales: | Fang, Qiyu, Wan, Xiaoying, D’Aiello, Angelica, Sun, Hui, Gu, Weiquing, Li, Yixue, Zhou, Caicun, Xie, Boxiong, Deng, Qinfang, Cheng, Haiying, Zhou, Songwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368968/ https://www.ncbi.nlm.nih.gov/pubmed/37503313 http://dx.doi.org/10.3389/fonc.2023.1116809 |
Ejemplares similares
-
Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis
por: Wan, Xiaoying, et al.
Publicado: (2022) -
Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer
por: Deng, Qinfang, et al.
Publicado: (2020) -
Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients
por: Deng, Qinfang, et al.
Publicado: (2018) -
Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer
por: D’Aiello, Angelica, et al.
Publicado: (2023) -
Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis
por: Deng, Qinfang, et al.
Publicado: (2020)